BR112014028632A2 - composto , composição farmacêutica , e , métodos de prepara um composto e de tratamento de uma infecção viral - Google Patents
composto , composição farmacêutica , e , métodos de prepara um composto e de tratamento de uma infecção viralInfo
- Publication number
- BR112014028632A2 BR112014028632A2 BR112014028632A BR112014028632A BR112014028632A2 BR 112014028632 A2 BR112014028632 A2 BR 112014028632A2 BR 112014028632 A BR112014028632 A BR 112014028632A BR 112014028632 A BR112014028632 A BR 112014028632A BR 112014028632 A2 BR112014028632 A2 BR 112014028632A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- treating
- preparing
- methods
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 208000036142 Viral infection Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648700P | 2012-05-18 | 2012-05-18 | |
| US201261659516P | 2012-06-14 | 2012-06-14 | |
| US201261666286P | 2012-06-29 | 2012-06-29 | |
| US201361774991P | 2013-03-08 | 2013-03-08 | |
| PCT/EP2013/060266 WO2013171334A1 (en) | 2012-05-18 | 2013-05-17 | Methanethione compounds having antiviral activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112014028632A2 true BR112014028632A2 (pt) | 2017-06-27 |
| BR112014028632A8 BR112014028632A8 (pt) | 2018-04-03 |
| BR112014028632B1 BR112014028632B1 (pt) | 2020-01-28 |
Family
ID=48444409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014028632A BR112014028632B1 (pt) | 2012-05-18 | 2013-05-17 | composto, composição farmacêutica, e, método para preparar um composto |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9359310B2 (pt) |
| EP (1) | EP2870141B1 (pt) |
| JP (2) | JP6484168B2 (pt) |
| KR (1) | KR102092207B1 (pt) |
| CN (1) | CN104540810B (pt) |
| AU (1) | AU2013261735B2 (pt) |
| BR (1) | BR112014028632B1 (pt) |
| CA (1) | CA2879816C (pt) |
| CL (1) | CL2014003116A1 (pt) |
| DK (1) | DK2870141T3 (pt) |
| EA (1) | EA029044B1 (pt) |
| ES (1) | ES2657942T3 (pt) |
| HK (1) | HK1210165A1 (pt) |
| IL (1) | IL235742A0 (pt) |
| IN (1) | IN2014DN10658A (pt) |
| MX (1) | MX356846B (pt) |
| MY (1) | MY169094A (pt) |
| NZ (1) | NZ702073A (pt) |
| SG (1) | SG11201407703QA (pt) |
| WO (1) | WO2013171334A1 (pt) |
| ZA (1) | ZA201409220B (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014DN10658A (pt) * | 2012-05-18 | 2015-08-28 | Vironova Ab | |
| CN107056762B (zh) * | 2016-12-22 | 2020-08-28 | 四川百利药业有限责任公司 | 一种用作抗流感病毒的双羰基类似物 |
| WO2021204924A1 (en) | 2020-04-09 | 2021-10-14 | Vironova Medical Ab | Compounds for use in the treatment of hypercytokinemia |
| WO2021204923A1 (en) | 2020-04-09 | 2021-10-14 | Vironova Medical Ab | Antiviral agents |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6642390B2 (en) | 2001-07-11 | 2003-11-04 | Lexicon Pharmaceuticals, Inc. | One step synthesis of 1,2,3-triazole carboxylic acids |
| AU2004218260A1 (en) * | 2003-01-28 | 2004-09-16 | Aventis Pharma S.A. | N-aryl heteroaromatic products, compositions containing same and use thereof |
| WO2009131957A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
| AU2010281265A1 (en) * | 2009-08-05 | 2012-03-22 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
| MX2013003227A (es) * | 2010-09-28 | 2013-05-31 | Bristol Myers Squibb Co | Nuevos analogos de piperazina con grupos heteroarilo sustituidos como antivirales de la influenza de espectro amplio. |
| EP2484655A1 (en) | 2011-02-04 | 2012-08-08 | Vironova AB | A thionation process and a thionating agent |
| IN2014DN10658A (pt) * | 2012-05-18 | 2015-08-28 | Vironova Ab | |
| JP6762767B2 (ja) * | 2016-06-01 | 2020-09-30 | キヤノン株式会社 | 撮像素子、撮像装置、および撮像信号処理方法 |
-
2013
- 2013-05-17 IN IN10658DEN2014 patent/IN2014DN10658A/en unknown
- 2013-05-17 ES ES13722781.5T patent/ES2657942T3/es active Active
- 2013-05-17 MY MYPI2014003200A patent/MY169094A/en unknown
- 2013-05-17 JP JP2015512081A patent/JP6484168B2/ja active Active
- 2013-05-17 MX MX2014014007A patent/MX356846B/es active IP Right Grant
- 2013-05-17 SG SG11201407703QA patent/SG11201407703QA/en unknown
- 2013-05-17 CN CN201380038170.2A patent/CN104540810B/zh active Active
- 2013-05-17 DK DK13722781.5T patent/DK2870141T3/da active
- 2013-05-17 KR KR1020147035090A patent/KR102092207B1/ko active IP Right Grant
- 2013-05-17 EP EP13722781.5A patent/EP2870141B1/en active Active
- 2013-05-17 AU AU2013261735A patent/AU2013261735B2/en active Active
- 2013-05-17 WO PCT/EP2013/060266 patent/WO2013171334A1/en active Application Filing
- 2013-05-17 CA CA2879816A patent/CA2879816C/en active Active
- 2013-05-17 BR BR112014028632A patent/BR112014028632B1/pt not_active IP Right Cessation
- 2013-05-17 EA EA201401277A patent/EA029044B1/ru not_active IP Right Cessation
- 2013-05-17 NZ NZ702073A patent/NZ702073A/en unknown
- 2013-05-17 US US14/401,545 patent/US9359310B2/en not_active Expired - Fee Related
-
2014
- 2014-11-17 CL CL2014003116A patent/CL2014003116A1/es unknown
- 2014-11-17 IL IL235742A patent/IL235742A0/en active IP Right Grant
- 2014-12-15 ZA ZA2014/09220A patent/ZA201409220B/en unknown
-
2015
- 2015-11-09 HK HK15110998.4A patent/HK1210165A1/xx unknown
-
2017
- 2017-11-09 JP JP2017216649A patent/JP2018065817A/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US9359310B2 (en) | 2016-06-07 |
| HK1210165A1 (en) | 2016-04-15 |
| KR20150012289A (ko) | 2015-02-03 |
| CN104540810A (zh) | 2015-04-22 |
| EP2870141A1 (en) | 2015-05-13 |
| MX356846B (es) | 2018-06-18 |
| AU2013261735B2 (en) | 2017-07-20 |
| BR112014028632A8 (pt) | 2018-04-03 |
| EP2870141B1 (en) | 2017-11-22 |
| CL2014003116A1 (es) | 2015-08-07 |
| ES2657942T3 (es) | 2018-03-07 |
| SG11201407703QA (en) | 2015-01-29 |
| WO2013171334A1 (en) | 2013-11-21 |
| IN2014DN10658A (pt) | 2015-08-28 |
| JP2018065817A (ja) | 2018-04-26 |
| CA2879816C (en) | 2020-07-07 |
| CA2879816A1 (en) | 2013-11-21 |
| US20150133468A1 (en) | 2015-05-14 |
| EA201401277A1 (ru) | 2015-04-30 |
| BR112014028632B1 (pt) | 2020-01-28 |
| KR102092207B1 (ko) | 2020-03-23 |
| NZ702073A (en) | 2017-07-28 |
| CN104540810B (zh) | 2017-01-18 |
| ZA201409220B (en) | 2016-08-31 |
| AU2013261735A1 (en) | 2015-01-22 |
| JP6484168B2 (ja) | 2019-03-13 |
| MY169094A (en) | 2019-02-18 |
| MX2014014007A (es) | 2015-05-11 |
| EA029044B1 (ru) | 2018-02-28 |
| DK2870141T3 (da) | 2018-01-29 |
| IL235742A0 (en) | 2015-02-01 |
| JP2015517516A (ja) | 2015-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL244431A0 (en) | Pharmacy methods and preparations for the treatment of hepatitis b virus infection | |
| IL251327B (en) | Antiviral compounds, preparations containing them and their use for the treatment of Arnavirus infections | |
| HK1203944A1 (zh) | 用於治療和預防乙型肝炎病毒感染的 -甲基-二氫嘧啶類 | |
| ZA201405820B (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
| ZA201500921B (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diaseases | |
| BR112014010545A2 (pt) | composição farmacêutica, método para tratar um paciente infectado com vírus da hepatite c, uso de uma composição | |
| HK1212905A1 (zh) | 用於防止登革熱病毒感染的疫苗組合物 | |
| BR112013010738A2 (pt) | composto, composição farmacêutica, e, método para tratar uma infecção viral | |
| HK1206986A1 (en) | Prophylactic/therapeutic agent for influenza virus infection | |
| EP2931310A4 (en) | COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS | |
| DK2939665T3 (da) | Farmaceutisk sammensætning til behandling af hiv-infektioner | |
| DK2900259T3 (da) | Glycosidase-regime til behandling af infektionssygdomme | |
| BR112014003556A2 (pt) | método de tratamento de vírus, e, composição farmacêutica | |
| BR112014028632A2 (pt) | composto , composição farmacêutica , e , métodos de prepara um composto e de tratamento de uma infecção viral | |
| HK1213816A1 (zh) | 治療 型肝炎病毒感染的醫藥組合物 | |
| KR101501876B9 (ko) | 자일리톨을 유효성분으로 함유하는 인플루엔자 바이러스 감염증 예방 또는 치료용 조성물 | |
| ZA201307019B (en) | Compositions for preventing and/or treating and infection by an hiv-1 virus | |
| CO6801768A2 (es) | Procesos para la preparación de inhibidores del virus de la hepatitis | |
| EP2931040A4 (en) | METHOD AND COMPOSITIONS FOR TREATING HIV INFECTIONS | |
| HK1205680A1 (en) | Agent for the treatment of hepatitis c virus | |
| ZA201306878B (en) | Treatment of hepatitis c virus infection with alisporivir | |
| HK1209647A1 (en) | Dengue virus vaccine composition | |
| ZA201407866B (en) | Composition for the prevention and treatment of viral infections caused by retroviruses | |
| HK1141664A2 (en) | Composition for the treatment of infection with human influenza viruses | |
| AU2013369626A1 (en) | Dengue virus vaccine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: VIRONOVA INFLUENZA AB (SE) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/05/2013, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2775 DE 12-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |